• Explore /
  • Poster
  • / Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK).

Phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib) (Cyto-KIK).

Abstract Video & Slides Poster

Authors

null

Karie Runcie

New York Presbyterian- Columbia, New York, NY

Karie Runcie , Eric A. Singer , Moshe Chaim Ornstein , Christopher B. Anderson , Matthew Dallos , Jessica Hawley , Emerson A. Lim , Charles G. Drake , Benjamin Izar , Hiram A. Shaish , Mark N. Stein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

AAAS6927

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr TPS371)

DOI

10.1200/JCO.2021.39.6_suppl.TPS371

Abstract #

TPS371

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Karie Runcie

First Author: Karie Runcie

First Author: Aly-Khan A. Lalani

First Author: Aly-Khan A. Lalani